Last reviewed · How we verify
NCT07480044
A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery
NA trial testing Transcranial Magnetic Stimulation Device in Postoperative Delirium (POD) in 220 participants. Not yet recruiting.
1 December 2028
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 220 |
| Start date | 20 March 2026 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Transcranial Magnetic Stimulation Device
Conditions studied
- Postoperative Delirium (POD) — all drugs for Postoperative Delirium (POD) →
- Prostate Cancer — all drugs for Prostate Cancer →
- Kidney Tumor — all drugs for Kidney Tumor →
Sponsor
Zhejiang University
Who can join
60 and older, any sex, with Postoperative Delirium (POD) or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cases were included based on the inclusion and exclusion criteria, and induction, maintenance, and recovery were conducted in accordance with the standard protocol for general anesthesia. After tracheal intubation and before tracheal tube removal at the end of the surgery, the parameters for iTBS stimulation frequency and duration were as follows: intensity was 80% of the active movement threshold, with 3 pulses per cluster at 50Hz, a frequency of 5Hz, 30 clusters of 10 pulses each, an 8 - second interval, and a single 600 - pulse; the 8 - shaped coil was connected to the electrodes in the designated head area (left frontal lobe cortex).Observation contents: Whether there is postoperative delirium and its severity: 3D - CAM assessment scale, DMAS assessment scale; awakening time, extubation time, PACU stay time, hospital stay time; 1 - 7 days after surgery or before discharge, POD assessment and pain - sleep assessment, the first time getting out of bed; postoperative complications; adverse reactions; adverse events, and so on.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07480044
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcranial Magnetic Stimulation Device
Trials testing the same drug.
- NCT06645613 — TMS With Real-time E-field and EEG Source Imaging · NA · not yet recruiting
Other recruiting trials for Postoperative Delirium (POD)
Currently open trials in the same condition.
- NCT06788743 — Impact of Sevoflurane Versus Propofol on Postoperative Delirium in Elderly Diabetic Patients Undergoing Non-Cardiac Surg · NA · recruiting
- NCT07324694 — Impact of Intraoperative Hemodynamic Instability on Outcomes in Cardiac Surgery · recruiting
- NCT06901479 — The Study of Postoperative Delirium and Glymphatic System Function in Cardiac Surgery · active not recruiting
- NCT06687291 — Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer · recruiting
- NCT06818409 — Is the CRP-Albumin-Lymphocyte (CALLY) Index Effective in Predicting Postoperative Delirium in Geriatric Patients Undergo · recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
- NCT07415525 — IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07480044 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07480044.